Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low – Should You Sell?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $18.69 and last traded at $18.83, with a volume of 260824 shares traded. The stock had previously closed at $19.54.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KLRA. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. TD Cowen began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price objective for the company. William Blair began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics presently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Down 2.8%

Insider Buying and Selling at Kailera Therapeutics

In other news, Director Andrew T. Kaplan purchased 8,398,438 shares of the business’s stock in a transaction on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the purchase, the director directly owned 26,255,581 shares in the company, valued at $420,089,296. The trade was a 47.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adam Koppel purchased 1,562,500 shares of the business’s stock in a transaction on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the purchase, the director owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. The trade was a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 10,460,938 shares of company stock worth $167,375,008 over the last quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.